Neurology · Cough SuppressantRegulatory Approvalregulatorymid-term

FDA Accepts ANDA for Dextromethorphan Hydrobromide and Quinidine Sulfate by Sun Pharma

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Sun Pharma3 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/20/2026, 6:32:04 PM

Assessment confidence: 68% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of Sun Pharma's ANDA for Dextromethorphan Hydrobromide and Quinidine Sulfate signifies a potential shift in the competitive landscape of the cough suppressant market. Portfolio teams must evaluate the implications for market share and strategize accordingly to mitigate risks from increased competition. Regulatory context from FDA (FDA AP — DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE (ORIG)) supports the near-term read. Assessment grounded in 9 ranked evidence items (5 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market dynamics and consider strategies to counteract potential market share loss. The strongest clinical anchor is HFCWO Vest Plus Mechanical Cough Assist Versus Cough Assist Alone on Respiratory Infections in ALS: Pilot Trial (ClinicalTrials.gov), mechanism alignment (io ). In rare disease, 6 regulatory and 1 competitive items passed relevance filtering for Sun Pharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). This acceptance may enhance Sun Pharma's position in the cough suppressant market, potentially increasing competition against existing products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE (ORIG) (FDA). Sub-indication match (rare disease); Regulatory pathway relevance (nda). While the ANDA acceptance is a positive step for Sun Pharma, the timeline for final approval and subsequent market entry remains critical for assessing regulatory impacts on the competitive landscape.

Key Risks

Elevated medium regulatory exposure for Sun Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Sun Pharma's entry into the market could disrupt existing players, affecting their revenue and market positioning. Companies must prepare for potential price competition and shifts in consumer preference.
Upside for Sun Pharma may improve if A Study to Investigate the Effect of AZD6234, AZD9550, and Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Part (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of this approval on market dynamics and consider strategies to counteract potential market share loss.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for final approval and market entry, as well as competitor responses.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — AUVELITY (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — AUVELITY (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
Lessons Learned from our Roundtable with Rare Disease Advocates
FDAmedium relevance
Sub-indication match (rare disease)
FDA document
View source
FDA AP — ATROPINE SULFATE (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source

HFCWO Vest Plus Mechanical Cough Assist Versus Cough Assist Alone on Respiratory Infections in ALS: Pilot Trial
ClinicalTrials.govmedium relevance
Mechanism alignment (IO )
FDA document
View source
A Study to Investigate the Effect of AZD6234, AZD9550, and Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Part
ClinicalTrials.govmedium relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Assessment of the Efficacy of Highly Standardized Ginger and Perilla Nutraceutical (Dispepril®) in Improving Gastric and Intestinal Symptoms in Patients With Functional Dyspepsia
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
FDA Approves OTC Naloxone Nasal Spray Rextovy for Opioid Overdose
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
ULK1's role in cancer progression and its emerging therapeutic potential.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Sun Pharma
existing competitors

Commercial impact

medium

Sun Pharma's entry into the market could disrupt existing players, affecting their revenue and market positioning. Companies must prepare for potential price competition and shifts in consumer preference.

Regulatory impact

medium

While the ANDA acceptance is a positive step for Sun Pharma, the timeline for final approval and subsequent market entry remains critical for assessing regulatory impacts on the competitive landscape.

What to watch

Monitor the timeline for final approval and market entry, as well as competitor responses.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.